We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HbA1c Point-of-Care Test Reliably Diagnoses Diabetes

By LabMedica International staff writers
Posted on 11 Apr 2019
Print article
Image: The AfinionHbA1c assay cartridge is used to test for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, which is used to monitor metabolic control in patients with diabetes (Photo courtesy of Alere).
Image: The AfinionHbA1c assay cartridge is used to test for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, which is used to monitor metabolic control in patients with diabetes (Photo courtesy of Alere).
Glycated hemoglobin is a form of hemoglobin that is covalently bound to glucose. It is formed in a non-enzymatic glycation pathway by hemoglobin's exposure to plasma glucose.

By measuring glycated hemoglobin (HbA1c), clinicians are able to get an overall picture of what the average blood sugar levels have been over a period of weeks/months. Point-of-care (POC) hemoglobin A1c (HbA1c) testing has advantages over laboratory testing, but some questions have remained regarding the accuracy and precision of these methods.

Scientists collaborating with Abbott Rapid Diagnostics (San Diego, CA, USA) carried out a prospective and observational study using samples from 120 adults (mean age, 57 years; 56% women) across a range of HbA1c levels (4%-15%) that were taken by finger stick at three clinical sites in the USA. Four groups were formed based on HbA1c levels and categorized as low (4%-5.99%), threshold (6%-6.99%), medium (7%-9.99%) and high (more than 10%).

Venous blood samples were also taken from each participant, and three from each HbA1c group were analyzed using a POC test. The POC test assessed in the study was the Afinion HbA1c Dx test (Alere Technologies, Waltham, MA, USA). The precision of the POC test using venous blood was evaluated from samples run in four replicates on each of three test cartridge lots, twice per day for 10 consecutive days. The SD and CV by study site and overall were calculated.

The investigators found that using the point-of-care test with finger-stick and venous blood samples was “highly correlated” with the National Glycohemoglobin Standardization Program (NGSP) values. They also noted small bias results when comparing point-of-care testing by finger-stick testing (mean differential bias, –0.021%) and venous blood samples (mean differential bias, –0.005%). In addition, 97.5% of results from the finger-stick point-of-care tests and 97.1% of the venous blood point-of-care tests fell within 6% of the reference method from the Diabetes Control and Complications Trial. At least 92.5% of results are currently required to fall within this range by the NGSP, although the program will adjust the requirements to be 90% within 5% of the reference result this year. They noted that 95% of the finger-stick point-of-care test results and 93.3% of the venous blood POC test results fell within 5% of the reference in these new requirements.

The authors concluded that point-of-care HbA1c testing has the potential to expand patient access to diabetes diagnostic testing and expedite medical decisions and interventions aimed at the prevention of diabetes and its complications, particularly for those who face challenges in accessing traditional health care settings or attending multiple laboratory and physician follow-up appointments. The study was published on March 10, 2019, in the Journal of Diabetes Science and Technology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more